Compare e l f Beauty Inc (ELF) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
e l f Beauty Inc vs Sana Biotechnology Inc — how do they compare? e l f Beauty Inc trades at $108.44 (market cap $6.25B), while Sana Biotechnology Inc trades at $2.82 (market cap $836.71M). The key difference: e l f Beauty Inc is far larger — about 7.5× Sana Biotechnology Inc's market cap, and e l f Beauty Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold e l f Beauty Inc for 25 Days and Sana Biotechnology Inc for 23 Days on average.
| ELF | SANA | |
|---|---|---|
Market Cap | $6.25B | $836.71M |
Volume | 1,099,552 | 4,507,444 |
Sector | Consumer Staples | Health |
52-Week High | $144.97 | $5.92 |
52-Week Low | $49.57 | $2.68 |
Typical Hold Time | 25 Days | 23 Days |
Enterprise Value | $6.84B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ELF Beauty trades at $107.95, up 2.78% with bullish technical signals and strong earnings beats. The stock shows robust revenue growth reaching $1.31B in 2025, though net margins compressed to 3.38% in 2026. Recent expansion includes rhode brand launches in Europe via Sephora and innovative marketing through original music albums. Analyst sentiment leans positive with 48% buy ratings despite a consensus price target of $95.91 below current levels.
Outlook remains growth-focused with international expansion driving opportunities, but premium valuation (P/E 108) and margin pressure pose risks. Institutional accumulation and technical strength support near-term upside, though investors should monitor execution on global growth initiatives against high expectations.
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About e l f Beauty Inc
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
